Pular para o conteúdo principal
Ranking Invest

HRTX - Heron Therapeutics, Inc.

Segmento: HealthcareHeron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Análise Ranking Invest

Valor de Mercado
$ 57.09 Mi
IVR
-3.23Índice proprietário de comparação relativa: -3,23.
IVR2
-3.39Leitura proprietária complementar: -339%.
MLL
-3.39Leitura proprietária complementar: -339%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 6.91 Mi

Dívida Líquida

-$ 20.72 Mi

L4T

-$ 34.05 Mi

MM4T

-22.75%

Indicadores Básicos

ROE

-492.89%

Índices de Previsibilidade

Receita Líquida

C0.05

Lucro

E1.86

Margem

E1.67

Índices de Tendência

Receita Líquida

B9.81

Lucro

A8.48

Margem

A8.83

Índices de Endividamento

DIV/PAT

-3.00

DIV/L4T

0.61

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.